Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety Trial of rfhSP-D to Prevent Neonatal Chronic Lung Disease
NCT05898633Phase 1Completed
- Sponsor
- University College London
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zelpultide alfa in bronchopulmonary dysplasia (BPD) and respiratory distress syndrome (RDS), sponsored by University College London. Primary endpoints: Occurrence of Dose Limiting Events and Recommended Phase 2 Dose. Started Apr 2024; status: completed.
02
Drugs
zelpultide alfa
03
Conditions
bronchopulmonary dysplasia (BPD)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT05898633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898633.